Methods for treating juvenile idiopathic arthritis by inhibition of TNFα
AssigneeAbbVie Biotechnology Ltd.
InventorsJohn R. Medich, Susan K. Paulson, Peter A. Noertersheuser
Life of this patent
Estimating the term…
Abstract
The invention provides methods and compositions for the treatment of juvenile idiopathic arthritis (JIA) where a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof, is used to treat JIA. In particular, the invention is directed to methods and compositions relating to a fixed dosing regimen for treating JIA with a TNFα inhibitor.
Claims19
A method for treating juvenile idiopathic arthritis (JIA) in a subject comprising administering an isolated human anti-TNFα antibody, or an antigen-binding portion thereof, to the subject, wherein 20 mg of the anti-TNFα antibody, or antigen-binding portion thereof, is administered to the subject if the subject weighs less than 30 kg, or wherein 40 mg of the anti-TNFα antibody, or antigen-binding portion thereof, is administered to the subject if the subject weighs more than or equal to 30 kg.
A method for treating juvenile idiopathic arthritis (JIA) in a subject comprising subcutaneously administering an isolated human anti-TNFα antibody, or antigen-binding portion thereof, to the subject, wherein 20 mg of the anti-TNFα antibody, or antigen-binding portion thereof, is administered to the subject if the subject weighs less than 30 kg, or wherein 40 mg of the anti-TNFα antibody, or antigen-binding portion thereof, is administered to the subject if the subject weighs more than or equal to 30 kg.
A method for treating juvenile idiopathic arthritis (JIA) in a subject comprising administering an isolated human anti-TNFα antibody, or an antigen-binding portion thereof to the subject, wherein a mean steady state trough serum concentration of the anti-TNFα antibody, or antigen-binding portion thereof is about 6 to 7 μg/mL or about 8 to 9 μg/mL,
- wherein 20 mg of the anti-TNFα antibody, or antigen-binding portion thereof, is administered to the subject if the subject weighs less than 30 kg, or wherein 40 mg of the anti-TNFα antibody, or antigen-binding portion thereof, is administered to the subject if the subject weighs more than or equal to 30 kg,
- and wherein the human anti-TNFα antibody, or an antigen-binding portion thereof, comprises a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO:
- 1 and a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO:
- 2.
A method for treating juvenile idiopathic arthritis (JIA) in a subject comprising administering an isolated human anti-TNFα antibody, or antigen-binding portion thereof to the subject, wherein a mean steady state trough serum concentration of the human anti-TNFα antibody, or antigen-binding portion thereof is about 10-11 μg/mL,
- wherein 20 mg of the anti-TNFα antibody, or antigen-binding portion thereof, is administered to the subject if the subject weighs less than 30 kg, or wherein 40 mg of the anti-TNFα antibody, or antigen-binding portion thereof, is administered to the subject if the subject weighs more than or equal to 30 kg,
- and wherein the human anti-TNFα antibody, or an antigen-binding portion thereof, comprises a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO:
- 1 and a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO:
- 2.
Dependencies are inferred from the claim text.